Previous 10 | Next 10 |
Lantern Pharma ( NASDAQ: LTRN ) on Thursday said the U.S. Food and Drug Administration (FDA) had granted an orphan drug designation to its LP-284 candidate for the treatment of mantle cell lymphoma (MCL). MCL is a rare and aggressive form of B-cell non-Hodgkin's lymphoma that is typic...
The Orphan Drug Designation strengthens LP-284’s clinical development path and provides the opportunity for additional market exclusivity and commercial protection. Lantern is anticipating filing the IND with the FDA and initiating a first-in-human Phase 1 trial for LP-284 in B-cell no...
New data from in vitro, in vivo, and IND enabling studies supports LP-284’s development for MCL, an aggressive form of B-cell non-Hodgkin's lymphoma (NHL) with immediate patient needs. Lantern is anticipating filing the IND with the FDA in early 2023 and initiating a first-in-human Pha...
New preclinical results presented at SABCS demonstrate LP-184 has superior anti-tumor efficacy for TNBC, as compared to current TNBC standard of care agents. LP-184 has therapeutic potential not only for primary TNBCs, but also for brain metastases (mets.) stemming from primary TNBC tumors. ...
Lantern Pharma (NASDAQ: LTRN) , a clinical-stage biopharmaceutical company using its proprietary RADR(R) artificial intelligence (“AI”") and machine learning platform to transform the cost, pace, and timeline of oncology drug discovery and development, will be participating i...
DALLAS, Dec. 02, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- Lantern Pharma Inc (Nasdaq: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR ® artificial intelligence ("A.I.") and machine learning (“M.L.”) platform to transform the cost, pace,...
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR ® artificial intelligence ("A.I.") and machine learning (“M.L.”) platform to transform the cost, pace, and timeline of oncology drug discovery and development...
Lantern Pharma Inc. (LTRN) Q3 2022 Results Conference Call November 07, 2022 04:30 PM ET Company Participants Panna Sharma - President and CEO David Margrave - CFO Nicole Leber - Investor Relations Conference Call Participants John Vandermosten - Zack...
Lantern Pharma press release ( NASDAQ: LTRN ): Q3 GAAP EPS of -$0.21 beats by $0.27 . Cash, cash equivalents, and marketable securities were approximately $57.8 million as of September 30, 2022 For further details see: Lantern Pharma GAAP EPS of -$0.21 beats ...
The Harmonic™ clinical trial activated the first two clinical trial sites for a Phase 2 study in never-smoker patients with non-small lung cancer and anticipates multiple additional sites in the US during 2022 IND-enabling studies for both LP-184 and LP-284 are expected to ...
News, Short Squeeze, Breakout and More Instantly...
Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging artificial intelligence (AI) and machine learning to transform the cost, pace, and timeline of oncology drug discovery and development, today announced a significant advancement towards the development of a diagn...
LP-284 is currently in a Phase 1 clinical trial, having been developed with guidance from Lantern’s AI platform, RADR ® , as a potential therapy for relapsed or refractory non-Hodgkin’s lymphoma and certain genomically defined sarcomas. LP-284 is the third molecule brou...
Active clinical trials across three AI-guided drug candidates with initial data and clinical readouts for LP-184 on-track for the second half of 2024. Obtained regulatory allowance to begin Phase 2 Harmonic™ clinical trial enrollment in Japan and Taiwan where approximately 30-35+% ...